This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cosmo Pharmaceuticals S.p.A.
Drug Names(s): BXL628
Description: BXL628 is a novel vitamin D3 analog and is a nonhypercalcemic vitamin D receptor agonist.
Proliferation of prostate cells, as in benign prostatic hyperplasia (BPH), is inhibited by binding of agonists such as vitamin D3 to the vitamin D receptor expressed on the prostate cell surface.
BXL628 also prevents RhoA activation and inhibits RhoA/Rho kinase signaling in the human bladder. This pathway plays a role in the regulation of smooth muscle contraction.
Vitamin D and its receptor may also play a role in male fertility, according to preclinical studies.
Deal Structure: BXL 628 was originally developed by Roche. BioXell is a Roche spin-out and was permitted to develop BXL 628 for benign prostatic hyperplasia (BPH), secondary hyperparathyroidism, transplant rejection and type I diabetes.
In June 2004, BioXell announced that it purchased additional indications from Roche for BXL 628. Under the new agreement, Roche granted BioXell exclusive worldwide development rights to BXL 628 for all non-topical and non-dermatological applications.
In November 2009, BioXell announced that it entered into a transaction agreement with Cosmo Pharmaceuticals under which the parties have agreed on the terms and conditions according to which Cosmo will launch a public tender offer for all outstanding shares of BioXell.
Pink Sheet R&D IN BRIEF
Additional information available to subscribers only: